DRMA
What one share of Dermata Therapeutics holds
Pharmaceutical Preparations
We are a late-stage medical dermatology company focused on identifying, developing, and commercializing innovative pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications we believe represent significant market opportunities.
Dermata Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.33 |
|---|---|
| Cash and investments | $1.10 |
| Book value | $0.87 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$254.04 | — | −$316.21 | — | −$249.44 |
| 2021 | — | −$364.86 | — | −$198.50 | — | $182.03 |
| 2023 | — | −$399.88 | — | −$328.78 | — | $242.56 |
| 2024 | — | −$80.32 | — | −$72.97 | — | $6.20 |
| 2025 | — | −$8.16 | — | −$8.42 | — | $2.34 |